Compare GSK plc (GSK) vs PulteGroup, Inc. (PHM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs PulteGroup, Inc. — how do they compare? GSK plc trades at $46.82 (market cap $91.88B), while PulteGroup, Inc. trades at $113.37 (market cap $21.63B). The key difference: GSK plc is far larger — about 4.2× PulteGroup, Inc.'s market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and PulteGroup, Inc. for 91 Days on average.
| GSK | PHM | |
|---|---|---|
Market Cap | $91.88B | $21.63B |
Volume | 7,730,529 | 2,324,729 |
Sector | Health | Consumer Cyclical |
52-Week High | $61.18 | $142.56 |
52-Week Low | $43.24 | $110.11 |
Typical Hold Time | 93 Days | 91 Days |
Enterprise Value | $111.88B | $22.04B |
Dividend Yield | 3.9% | 0.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $47.02, up 0.9% with a P/E of 14.89, trading below industry averages. The stock shows strong profitability with 72.73% gross margins and 29.73% ROE, though technical indicators signal bearish momentum. Recent earnings beats and strategic oncology investments highlight growth potential amid patent cliff concerns.
GSK's valuation appears attractive with earnings momentum, but faces headwinds from technical weakness and HIV patent expirations. The bullish analyst sentiment (31% buy ratings) and pipeline innovation provide upside, while cost-saving initiatives and dividend yield offer stability. Key risks include competitive pressures and execution on £40B sales targets.
PulteGroup (PHM) trades at $112.33, down 3.25% amid broader housing sector weakness driven by rising mortgage rates. The stock shows bearish technical signals with key support at $110, while fundamentals reveal solid profitability with 11.62% net margin and attractive valuation at P/E of 11.6. Recent earnings show mixed results with Q2 beat but Q4 and Q1 misses, with Q3 results pending. The company maintains strong cash flow generation with $355M net cash flow in 2025.
PHM presents a value opportunity with below-market valuation and consistent profitability, though near-term headwinds from rising rates pressure housing demand. Analyst consensus targets $139.80 (24% upside) with 45% buy ratings, but technical weakness and macroeconomic risks require careful monitoring. The dividend yield provides income support during market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About PulteGroup, Inc.
PulteGroup Inc is one of the largest homebuilders in the United States, operating in 40 markets across 23 states. The company mainly builds single-family detached homes (85% of unit sales) and offers products to entry-level, move-up, and active-adult buyers. PulteGroup offers homebuyers mortgage financing and title agency services through its financial services segment. The company is headquartered in Atlanta.
Read more on PHM →
